SRR8518451
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.540
- ANGIOGENESIS+0.420
- COAGULATION+0.380
- PANCREAS_BETA_CELLS+0.310
- MYOGENESIS+0.300
- IL6_JAK_STAT3_SIGNALING+0.290
- COMPLEMENT+0.270
- UV_RESPONSE_DN+0.260
- KRAS_SIGNALING_UP+0.230
- INFLAMMATORY_RESPONSE+0.220
Top 10 suppressed
- E2F_TARGETS-0.610
- G2M_CHECKPOINT-0.600
- MYC_TARGETS_V2-0.600
- MYC_TARGETS_V1-0.560
- MITOTIC_SPINDLE-0.400
- MTORC1_SIGNALING-0.400
- UNFOLDED_PROTEIN_RESPONSE-0.400
- DNA_REPAIR-0.370
- OXIDATIVE_PHOSPHORYLATION-0.360
- INTERFERON_ALPHA_RESPONSE-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8613742 | — | A | 0.915 |
| 2 | TCGA-55-8096-01A-11R-2241-07 | — | cohortA1 | 0.895 |
| 3 | DRR168582 | — | — | 0.891 |
| 4 | MBCProject_1493_T1_RNA | — | A | 0.881 |
| 5 | SRR8518299 | — | A | 0.875 |
| 6 | TCGA-IQ-A61O-01A-11R-A30B-07 | — | — | 0.875 |
| 7 | SRR8518268 | — | A | 0.858 |
| 8 | SRR12475118 | — | — | 0.858 |
| 9 | 20040019.LumA | — | A | 0.856 |
| 10 | SRR25617862 | — | A | 0.855 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.540 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| COAGULATION | 0.380 | Binimetinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| COMPLEMENT | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.230 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.220 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.210 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.100 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.080 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.020 | Temsirolimus | — uncovered |